Select language:

COVID-19 drug patented in Russia

 / Главная / Russkiy Mir Foundation / News / COVID-19 drug patented in Russia

COVID-19 drug patented in Russia


07.08.2020

Photo credit: doc-tv.ru

The anti-coronavirus drug has been patented in Russia, RIA Novosti reports. Leitragin can prevent or reduce complications that occur after infection. The Federal Biomedical Agency (FMBA) noted that it is the first and so far the only delta-opioid receptor agonist in the world to enter practical medicine.

Scientists from the FMBA Research Center for Biomedical Technologies have determined that the drug under the original name "Dalargin" has a positive effect on tissue healing and regeneration.

The researchers added that substances of this class were actively involved in the formation of an immune response, and can also prevent or mitigate a cytokine storm. This is a condition in which pro-inflammatory substances are actively released, which leads to the development of serious respiratory and general systemic disorders in patients infected with the new coronavirus.

As Russkiy Mir reported, Russia invented new methods for diagnosing and treating coronavirus. Buryat doctors use artificial intelligence for diagnostics. Graduate students of the National Research Nuclear Engineering Physics Institute of Biomedicine of Moscow Engineering Physics Institute developed an LED installation for the safe treatment of serious diseases. The development is successfully used in the treatment of patients with COVID-19.

Russkiy Mir

News by subject

Publications

Italian entrepreneur Marco Maggi's book, "Russian to the Bone," is now accessible for purchase in Italy and is scheduled for release in Russia in the upcoming months. In the book, Marco recounts his personal odyssey, narrating each stage of his life as a foreigner in Russia—starting from the initial fascination to the process of cultural assimilation, venturing into business, fostering authentic friendships, and ultimately, reaching a deep sense of identifying as a Russian at his very core.